| Identification | More | [Name]
Nalpha-Cbz-L-Arginine | [CAS]
1234-35-1 | [Synonyms]
CBZ-ARG-OH
CBZ-L-ARGININE
CBZ-L-ARG-OH
L-ARGININE, N2-[(PHENYLMETHOXY)CARBONYL]-
N2-CARBOBENZYLOXY-L-ARGININE
N-ALPHA-BENZYLOXYCARBONYL-L-ARGININE
NALPHA-CARBOBENZOXY-L-ARGININE
N-ALPHA-CARBOBENZYLOXY-L-ARGININE
NALPHA-CBZ-L-ARGININE
N-ALPHA-Z-L-ARGININE
N-BENZYLOXYCARBONYL-L-ARGININE
N-CARBOBENZOXY-L-ARGININE
N-CBZ-L-ARGININE-OH
Z-ARGININE
Z-ARG-OH
Z-L-ARGININE
Z-L-ARG-OH
n2-[(phenylmethoxy)carbonyl]-l-arginin
Nα-Z-L-Arginine
N2-Carbobenzyloxy-L-arginine
| [EINECS(EC#)]
214-973-6 | [Molecular Formula]
C14H20N4O4 | [MDL Number]
MFCD00001762 | [Molecular Weight]
308.33 | [MOL File]
1234-35-1.mol |
| Chemical Properties | Back Directory | [Appearance]
white powder | [Melting point ]
171-174 °C (dec.)(lit.) | [alpha ]
-11 º (c=0.5, 0.5N HCl 24 ºC) | [Boiling point ]
448.73°C (rough estimate) | [density ]
1.1765 (rough estimate) | [refractive index ]
-10 ° (C=5.5, 0.2mol/L HCl) | [storage temp. ]
2-8°C
| [solubility ]
DMSO, Water | [form ]
Solid | [pka]
3.90±0.21(Predicted) | [color ]
White | [optical activity]
[α]20/D 9±1°, c = 5% in 1 M HCl | [BRN ]
2169267 | [CAS DataBase Reference]
1234-35-1(CAS DataBase Reference) | [EPA Substance Registry System]
1234-35-1(EPA Substance) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed .
R36/37/38:Irritating to eyes, respiratory system and skin . | [Safety Statements ]
S24/25:Avoid contact with skin and eyes .
S36:Wear suitable protective clothing .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice . | [WGK Germany ]
3
| [TSCA ]
Yes | [HS Code ]
29252900 |
| Hazard Information | Back Directory | [Chemical Properties]
white powder | [Uses]
Z-L-Arginine is used in the synthesis of renin inhibitors containing phosphorous acid derivatives at the scissile bond. Also used in the synthesis of a peptide deformylase inhibitor BB-3497. | [reaction suitability]
reaction type: solution phase peptide synthesis |
|
|